Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Dosage Regimen: Individualization

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Dosage Regimens: Designs and Approaches

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Directional, scale-resolved measurement of underwater optical turbulence using multi-beam self-heterodyne detection.

Optics express·2026

Same author

Frequency-diverse structured light for optical gradient sensing using heterodyne interferometry.

Optics express·2026

Same author

Target Trial Emulation of Vaccine Effectiveness in 5- to 17-years-olds with Prior SARS-CoV-2 Infection.

Nature communications·2026

Same author

Pilot proteomics study for identifying a pollution exposure signature in firefighters.

Journal of exposure science & environmental epidemiology·2026

Same author

Epsilon-near-zero time-gate for high-fidelity spatial information transfer through dynamic scattering media.

Nature communications·2026

Same author

Cannibalism, predation, and refuges of juvenile blue crabs from a 37-year experiment.

Proceedings of the National Academy of Sciences of the United States of America·2026

Search research articles

Related Experiment Video

Updated: May 28, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Genotype-based dosing algorithms for warfarin therapy: data review and recommendations.

Eric G Johnson¹, Benjamin D Horne, John F Carlquist

¹Cardiovascular Department, Intermountain Medical Center, Salt Lake City, UT, USA.

Molecular Diagnosis & Therapy

|November 4, 2011

Summary

This summary is machine-generated.

Pharmacogenetic dosing for warfarin, using CYP2C9 and VKORC1 gene variants, shows potential but remains unproven in clinical practice. Ongoing trials and new anticoagulants question its future relevance and cost-effectiveness.

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Related Experiment Videos

Last Updated: May 28, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Area of Science:

Pharmacogenomics
Clinical Pharmacology
Genetics

Background:

Warfarin is a widely used oral anticoagulant.
Pharmacogenetic dosing aims to personalize warfarin therapy using genetic variants.
CYP2C9 and VKORC1 gene variants influence warfarin dose requirements.

Purpose of the Study:

To review and synthesize published clinical trials on pharmacogenetic warfarin dosing.
To assess the current evidence for genotype-guided warfarin therapy.
To discuss the future relevance of pharmacogenetic warfarin dosing in light of new anticoagulants and cost-benefit analyses.

Main Methods:

Review of published clinical trials, including randomized controlled trials.
Synthesis of study findings regarding the success and skepticism surrounding pharmacogenetic dosing.
Consideration of ongoing trials and emerging oral anticoagulants.

Main Results:

Studies show sequence variants in CYP2C9 and VKORC1 can predict warfarin dose.
Clinical trials report varying degrees of success, with some facing skepticism.
No studies to date have demonstrated a cost-benefit for genotype-guided warfarin dosing in clinical practice.

Conclusions:

Pharmacogenetic warfarin dosing, while theoretically promising, is currently unproven for clinical use.
The cost of genotype-guided dosing is substantial.
The emergence of new oral anticoagulants may impact the future role of pharmacogenetic warfarin dosing.